



Imugene Engages Mymetics to Manufacture HER-Vaxx Cancer Immunotherapy

Melbourne, 16 July 2014: Australian immuno-oncology company Imugene Limited (ASX:IMU) has engaged Mymetics SA, based in Switzerland, to exclusively manufacture and develop its cancer immunotherapy HER-Vaxx.

Mymetics brings specialist experience and know-how in the manufacturing, formulation and quality aspects of all types of virosomes, including influenza-based virosomes, the key delivery component in Imugene's peptide-based immunotherapy HER-Vaxx. Imugene had earlier announced the appointment of Bachem to manufacture the peptide component of HER-Vaxx.

HER-Vaxx is a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the US\$6.9 billion per annum drug Herceptin®. HER-Vaxx has successfully completed a Phase 1 study in breast cancer and the next stage of development will be a Phase 2 study in gastric cancer.

Dr Nick Ede, Executive Director Imugene said, "Mymetics uses the same vaccine delivery platform for infectious diseases that we are using for our immuno-oncology program and together both companies will work to exploit the potential value of influenza-based virosomes."

Ronald Kempers, CEO of Mymetics said: "We are proud that Imugene has decided to engage with Mymetics for the manufacturing of its proprietary HER-Vaxx immunotherapy. It further confirms and recognises Mymetics as a global leader and niche player in the development and formulation of virosomes and integration of membrane proteins and peptides for vaccine candidates."

-ends

Contact :

Paul A Hopper
Executive Chairman
+1 858 334 5820 (US)
+61 406 671 515 (Australia)
receptogen[at]earthlink.net

Dr Nick Ede
Executive Director
+61 400 642 254
nede[at]imugene.com

Media contact:

Rudi Michelson
Monsoon Communications
+61 3 9620 3333
rudim[at]monsoon.com.au

About Imugene: Imugene (ASX; IMU) is an immuno-oncology biopharmaceutical company developing HER2 +ve gastric and breast cancer immunotherapies. The Company's lead product is HER-Vaxx, a proprietary HER2 +ve cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer. Imugene's corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria. For more information on Imugene, please visit www.imugene.com

About Mymetics

Mymetics Corporation (OTC BB: MYMX) is a Swiss-based biotechnology company registered in the US (MYMX) developing next-generation preventative vaccines for infectious diseases. Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins, in combination with rationally designed antigens. The company's vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine. Mymetics currently has 5 vaccines in its pipeline: HIV-1/AIDS, intra nasal Influenza, Malaria, Herpes Simplex Virus and the RSV vaccine (out licensed to ClearPath - Astellas). The company's HIV-1 vaccine has completed a Phase I clinical trial in healthy human volunteers. A Phase 1b clinical trial for its Malaria vaccine on children in Tanzania has been completed, while the HSV vaccine candidate is in the preclinical phase. For further information, please visit mymetics.com.